Cite
Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome.
MLA
Mestel, Dominik Sebastian, et al. “Zanolimumab, a Human Monoclonal Antibody Targeting CD4 in the Treatment of Mycosis Fungoides and Sézary Syndrome.” Expert Opinion on Biological Therapy, vol. 8, no. 12, Dec. 2008, pp. 1929–39. EBSCOhost, https://doi.org/10.1517/14712590802528696.
APA
Mestel, D. S., Beyer, M., Möbs, M., Steinhoff, M., Sterry, W., & Assaf, C. (2008). Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome. Expert Opinion on Biological Therapy, 8(12), 1929–1939. https://doi.org/10.1517/14712590802528696
Chicago
Mestel, Dominik Sebastian, Marc Beyer, Markus Möbs, Matthias Steinhoff, Wolfram Sterry, and Chalid Assaf. 2008. “Zanolimumab, a Human Monoclonal Antibody Targeting CD4 in the Treatment of Mycosis Fungoides and Sézary Syndrome.” Expert Opinion on Biological Therapy 8 (12): 1929–39. doi:10.1517/14712590802528696.